Research programme: oncolytic immunotherapies - Replimune

Drug Profile

Research programme: oncolytic immunotherapies - Replimune

Alternative Names: RP2; RP3; RP3 Series

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Replimune
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Nov 2017 Preclinical trials in Cancer in USA (Intratumoral)
  • 14 Nov 2017 Replimune plans a phase I trial for RP 2 and RP 3 in 2018
  • 08 Sep 2017 Replimune plans clinical trials for RP1 in Cancer in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top